Thursday 19 November 2026 Sign in / SubscribeFree daily emailMarket analysisEnterprise solutionsVigiEye regulatory newsCompePharma CRM & HR →
The business of pharma
Pipeline & R&D

Helus psilocin-based depression drug posts positive first Phase 3; second readout due late 2027

Helus Pharma's deuterated psilocin candidate HLP003 beat placebo on a standard depression scale in the first of two pivotal studies, leaving a Q4 2027 readout to set the filing timetable.

16 Nov 2026 · Helus Pharma Inc. HELP · Company news

Helus Pharma has delivered the first of the two pivotal datasets it needs for HLP003, a deuterated version of psilocin being developed as an add-on treatment for adults with major depressive disorder. The company announced the topline APPROACH results on 16 November 2026. It did not disclose pricing, revenue forecasts, partnering plans or launch timing, so the commercial implications are still open.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on CompePharma and VigiEye
  • One subscription for both sites, cancel any time
Continue with Google
or
You'll be signed in straight away; we also email you a link to confirm your address. Reading every article takes a $4.99/month subscription (secure checkout by Stripe), billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. See our terms and privacy policy.

Company's press release (SEC filing): Helus Pharma Inc. ↗

Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.

More Pipeline & R&DAll →